Acurx Pharmaceuticals, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Acurx Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $1.59M.
- Acurx Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $320.21K, a 90.96% decline year-over-year.
- Acurx Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $4.30M.
- Acurx Pharmaceuticals, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $3.54M.
- Acurx Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2022 was $3.70M, a 75.03% decline from fiscal 2021.
- Acurx Pharmaceuticals, Inc. stock issued during period, value, new issues for fiscal 2021 was $14.80M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-09-30 | $1.59M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $320.21K 10-Q · filed 2024-11-12 | |
| 2024-03-31 | $4.30M 10-Q · filed 2025-05-12 | |
| 2023-06-30 | $3.54M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $3.70M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $3.70M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $14.80M 10-K · filed 2023-03-15 | |
| 2021-06-30 | $14.80M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |